Cuál es el precio por Artiva Biotherapeutics, Inc. (ARTV)

Precio por Artiva Biotherapeutics, Inc. (ARTV) es de$11.09

Cuál es la capitalización de mercado por Artiva Biotherapeutics, Inc. (ARTV)

Capitalización de mercado por Artiva Biotherapeutics, Inc. (ARTV) es $542.19M

Artiva Biotherapeutics, Inc. (ARTV) Dividendos

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Año	Dividendo (ajustado por splits de acciones)	Cambiar
Not enough data for the provided dates.

Año

Dividendo (ajustado por splits de acciones)

Cambiar

Not enough data for the provided dates.

Año	Dividendo	Cambiar
Not enough data for the provided dates.

Año

Dividendo

Cambiar

Not enough data for the provided dates.

Empresa	Número de pagos de dividendos	País
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	64.00%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

Empresa

Número de pagos de dividendos

País